Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs

Journal of Nuclear Medicine

Volumn 44, Issue 12, 2003, Pages 2027-2032

  Schwartz, Jeffrey L ^a,b   Tamura, Yasuko ^a   Jordan, Robert ^a   Grierson, John R ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

2 fluoro 5 methyl 1 ( d 2 arabino furanosyl) uracil; 3 deoxy 3 fluorothymidine; Cell proliferation; Thymidine kinase

Indexed keywords

2' FLUORO 5 METHYL 1 (BETA 2 ARABINOFURANOSYL)URACIL; BETA 3' DEOXY 3' FLUOROTHYMIDINE; FLUOROURACIL; RADIOISOTOPE; THYMIDINE DERIVATIVE; THYMIDINE KINASE; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 2'-FLUORO-5-METHYLARABINOSYLURACIL; 3' FLUOROTHYMIDINE; CLEVUDINE; DIAGNOSTIC AGENT; DNA; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT; THYMIDINE; THYMIDINE KINASE 1; TRITIUM; URACIL ARABINOSIDE;

ANIMAL CELL; ARTICLE; BIOLOGICAL MONITORING; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PHASE TRANSITION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; ANIMAL; BIOSYNTHESIS; CANCER STAGING; CELL DIVISION; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DELIVERY SYSTEM; EVALUATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; ARABINOFURANOSYLURACIL; CELL DIVISION; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; DNA; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC CLEARANCE RATE; MICE; NEOPLASM STAGING; NEOPLASMS; RADIOPHARMACEUTICALS; THYMIDINE; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED; TRITIUM;

EID: 1542681635     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Begg AC Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol. 1994;65:103-108.
2. Dressler LG. DNA flow cytometry measurements as surrogate endpoints in chemoprevention trials: clinical, biological, and quality control considerations. J Cell Biochem Suppl. 1993;17G:212-218.
3. Hall EJ. Radiobiology for the Radiologist. New York, NY. Lippincott Williams & Wilkins; 2000:427-428.
4. Hoshino T, Prados M, Wilson CB, Cho KG, Lee KS, Davis RL Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 1989;71:335-341
5. Krohn, KA, Mankoff DA, Eary JF Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;41(suppl):96S-103S.
6. Mehdi SA, Etzell JE, Newman NB, Weidner N, Kohman LJ, Graziano SL Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 1998;20:99-108.
7. Struikmans H, Kal HB, Hordijk GJ, van der Tweel I. Proliferative capacity in head and neck cancer Head Neck. 2001;23:484-491.
8. West CM, Keng PC, Sutherland RM. Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys. 1988;14:1213-1219.
9. Leskinen-Kallio S Positron emission tomography in oncology. Clin Physiol 1994;14:329-335.
10. Maisey NR, Webb A, Flux GD, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas, a pilot study. Br J Cancer. 2000;83:287-293.
11. 11C]thymidine PET imaging studies: validation studies. J Nucl Med. 1999;40:614-624
12. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71-88.
13. Mankoff DA, Bellon JR. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol. 2001;11:16-27
14. 18F-Fluorothymidine PET imaging of non-small cell lung cancer (NSCLC): comparison to Ki-67 proliferation index [abstract]. J Nucl Med. 2001;42(suppl.):29P
15. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336
16. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23:17-22.
17. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252-258.
18. Weber WA, Avril N, Schwaiger M Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999;175:356-373.
19. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471-486.
20. Eary JF, Mankoff DA, Spence AM, et al 2-[C-11]thymidine imaging of malignant brain tumors Cancer Res. 1999;59:615-621
21. Bading JR, Shahinian AH, Bathija P, Conti PS Pharmacokinetics of the thymidine analog 2′-fluoro-5-[(14)C]-methyl-1-beta-D- arabinofuranosyluracil ([(14)C]F-MAU) in rat prostate tumor cells. Nucl Med Biol. 2000;27:361-368.
22. 124I]iododeoxyuridine. Cancer Res 2000;60:624-635
23. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
24. Hannigan BM, Barnett YA, Armstrong DB, McKelvey-Martin VJ, McKenna PG. Thymidine kinases the enzymes and their clinical usefulness. Cancer Biother. 1993;8:189-197.
25. Hengstschlager M, Knofler M, Mullner EW, Ogris E, Wintersberger E, Wawra E Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem. 1994;269:13836-13842.
26. Wintersberger E, Rotheneder H, Grabner M, Beck G, Seiser C. Regulation of thymidine kinase during growth, cell cycle and differentiation. Adv Enzyme Regul. 1992;32:241-254.
27. Tannock I Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep. 1978;62:1117-1133.
28. Bardot V, Dutrillaux AM, Delattre JY, et al. Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer. 1994;70:212-218.
29. Wei S, Reillaudou M, Apiou F, Peyre H, Petridis F, Luccioni C. Purine metabolism in two human melanoma cell lines: relation to proliferation and differentiation. Melanoma Res. 1999;9:351-359.
30. Cole PD, Smith AK, Kamen BA. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs. Cancer Chemother Pharmacol. 2002;50:111-116.
31. Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK. Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res. 2000;153:84-92.
32. Schwartz JL, Grierson JR, Rasey JS, Wiens L, Jordan R, Kohli T. Rates of accumulation and retention of 3′-deoxy-3′-fluorothymidine (FLT) in different cell lines [abstract]. J Nucl Med. 2001;42(suppl):283P.
33. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
34. 18F]fluoromisonidazole: a pre-therapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
35. Rasey JS, Carpenter RE, Nelson NJ, Parker RG. Cure of EMT-6 tumors by x rays or neutrons: effect of mixed-fractionation schemes. Radiology. 1977;123:207-212.